Back to Search
Start Over
The EGFR C797S Mutation Confers Resistance to a Novel EGFR Inhibitor CLN-081 to EGFR Exon 20 Insertion Mutations
- Source :
- JTO Clinical and Research Reports; March 2023, Vol. 4 Issue: 3
- Publication Year :
- 2023
-
Abstract
- EGFR exon 20 insertion mutations account for 5% to 10% of EGFR-mutated NSCLC. CLN-081 (formerly known as TAS6417), a novel covalent EGFR tyrosine kinase inhibitor, exhibits pan-mutation selective efficacy, including exon 20 insertions, in the clinical setting. Nevertheless, some patients may not respond to CLN-081 and resistance to CLN-081 may emerge over time in others.
Details
- Language :
- English
- ISSN :
- 26663643
- Volume :
- 4
- Issue :
- 3
- Database :
- Supplemental Index
- Journal :
- JTO Clinical and Research Reports
- Publication Type :
- Periodical
- Accession number :
- ejs62027925
- Full Text :
- https://doi.org/10.1016/j.jtocrr.2023.100462